UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
Investigational Vaccine for Melanoma

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence

Participants in this research study have a type of cancer known as melanoma. This study is designed to help determine how safe the investigational vaccine POL-103A is and how it works in humans who have melanoma.

This study will test two different doses of the POL-103A vaccine and one dose of placebo (an injection that will feel like the POL-103A injection but contains no vaccine). This is a blinded study. This means neither the participant or the study doctor will know if the participant is receiving the higher dose of the vaccine, the lower dose of vaccine, or the placebo dose.

Study treatment can last as long as 24 months. With follow up continuing every 3 months.

Start Date
August 15, 2012
End Date
August 15, 2022
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Mohammed Milhem, MD
Contact Info

Melanie Frees, 319-356-1228

cancer ; high risk recurrence ; IRB#201204506 ; melanoma ; milhem ; phase 3 ; phase III ; POL-103A polyvalent melanoma vaccine ; Post-resection Melanoma ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.